Home / Market Reports / Pharma & Healthcare
/ Global Transthyretin (TTR) Modulators Market Growth 2024-2030
Global Transthyretin (TTR) Modulators Market Growth 2024-2030
Product Code:1243552
Published Date: Dec 07,2024
Pages: 81
Region: Global
Category: Pharma & Healthcare
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
The global Transthyretin (TTR) Modulators market size is predicted to grow from US$ 5752 million in 2024 to US$ 9070 million in 2030; it is expected to grow at a CAGR of 7.9% from 2024 to 2030.
TTR modulators are drugs designed to regulate the key target of transthyroxin protein (TTR), the core goal of which is to effectively treat a series of diseases closely related to TTR by adjusting the function or stability of TTR. By precisely targeting TTR, TTR modulators offer a new therapeutic avenue for patients with these diseases and are expected to significantly improve their quality of life.
United States market for Transthyretin (TTR) Modulators is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Transthyretin (TTR) Modulators is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Transthyretin (TTR) Modulators is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Transthyretin (TTR) Modulators players cover BridgeBio Pharma, Inc, AstraZeneca AB, Medison Pharma Australia Pty Ltd, Pfizer Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
LP Information, Inc. (LPI) ' newest research report, the “Transthyretin (TTR) Modulators Industry Forecast” looks at past sales and reviews total world Transthyretin (TTR) Modulators sales in 2023, providing a comprehensive analysis by region and market sector of projected Transthyretin (TTR) Modulators sales for 2024 through 2030. With Transthyretin (TTR) Modulators sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transthyretin (TTR) Modulators industry.
This Insight Report provides a comprehensive analysis of the global Transthyretin (TTR) Modulators landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Transthyretin (TTR) Modulators portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transthyretin (TTR) Modulators market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transthyretin (TTR) Modulators and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transthyretin (TTR) Modulators.
This report presents a comprehensive overview, market shares, and growth opportunities of Transthyretin (TTR) Modulators market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Small Interfering RNA
Small Molecule Drugs
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
BridgeBio Pharma, Inc
AstraZeneca AB
Medison Pharma Australia Pty Ltd
Pfizer Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Transthyretin (TTR) Modulators market?
What factors are driving Transthyretin (TTR) Modulators market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Transthyretin (TTR) Modulators market opportunities vary by end market size?
How does Transthyretin (TTR) Modulators break out by Type, by Application?